Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study

被引：0
|
作者：
Lale Atahan
Ferah Yıldız
Mustafa Cengiz
Bunyamin Kaplan
Metin Özkan
Gozde Yazici
Mete Gündoğ
Ayfer Haydaroğlu
Aylin F. Korcum
Meriç Şengöz
Maktav Dinçer
Müge Akmansu
Kayıhan Engin
Mutlu Hayran
机构：
[1] Hacettepe University,Department of Radiation Oncology
[2] Erciyes University,Department of Radiation Oncology
[3] Ankara Education and Investigation Hospital of Ministry of Health,Department of Radiation Oncology
[4] Ege University,Department of Radiation Oncology
[5] Akdeniz University,Department of Radiation Oncology
[6] Marmara University,Department of Radiation Oncology
[7] İstanbul University,Department of Radiation Oncology
[8] Gazi University,Department of Radiation Oncology
[9] Uludağ University,Department of Radiation Oncology
[10] Anadolu Sağlık Merkezi,Department of Preventive Oncology
[11] Hacettepe University,undefined
来源：
Supportive Care in Cancer | 2010年 / 18卷
关键词：
Bone metastasis; Breast cancer; Radiotherapy; Zoledronic acid;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 698
页数：7
相关论文
共 50 条
  • [41] Effect of Denosumab Versus Zoledronic Acid Treatment in Patients with Breast Cancer and Bone Metastases: Results from the Extended Blinded Treatment Phase
    Stopeck, A.
    Martin, M.
    Ritchie, D.
    Body, J-J
    Paterson, A.
    Viniegra, M.
    Jassem, J.
    Takano, T.
    Van Poznak, C.
    Bourgeois, H.
    Fan, M.
    Dansey, R.
    Braun, A.
    CANCER RESEARCH, 2010, 70
  • [42] Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 164 - 165
  • [43] Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid Subgroup Analysis from a Randomized Phase 3 Study
    Scagliotti, Giorgio Vittorio
    Hirsh, Vera
    Siena, Salvatore
    Henry, David H.
    Woll, Penella J.
    Manegold, Christian
    Solal-Celigny, Philippe
    Rodriguez, Gladys
    Krzakowski, Maciej
    Mehta, Nilesh D.
    Lipton, Lara
    Angel Garcia-Saenz, Jose
    Pereira, Jose Rodrigues
    Prabhash, Kumar
    Ciuleanu, Tudor-Eliade
    Kanarev, Vladimir
    Wang, Huei
    Balakumaran, Arun
    Jacobs, Ira
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (12) : 1823 - 1829
  • [44] PAIN INTERFERENCE OUTCOMES IN A RANDOMIZED PHASE 3 CLINICAL TRIAL OF DENOSUMAB VS ZOLEDRONIC ACID (ZA) IN PATIENTS WITH SOLID TUMORS AND BONE METASTASES
    Cleeland, C.
    Fallowfield, L.
    von Moos, R.
    Patrick, D.
    Henry, D. H.
    Hirsh, V.
    Zarogoulidis, K.
    Feng, A.
    Cong, Z.
    Braun, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 509 - 510
  • [45] A Markov model to evaluate the coat effectiveness of intravenous (IV) zoledronic acid vs IV generic pamidronate or oral ibandronate in the prevention of bone complications in breast cancer patients with bone metastases.
    Stephens, JM
    Aapro, MS
    Botteman, MF
    Hay, JW
    Brandman, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 44S - 44S
  • [46] Cost effectiveness of intravenous (IV) zoledronic acid vs other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: A Markov model from the UK perspective.
    Botteman, MF
    Aapro, MS
    Hay, JW
    Stephens, JM
    Brandman, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 58S - 58S
  • [47] Predictors of skeletal-related events among cancer patients with bone metastases treated with zoledronic acid: a secondary analysis of a randomized study
    Abdel-Rahman, Omar
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 757 - 761
  • [48] High Dose Hypofractionated Stereotactic Body Radiation Therapy of Non Compressive Vertebral Bone Metastases in Combination With Zoledronic Acid: A Phase 1 Study
    Pichon, B.
    Mahe, M. A.
    Delpon, G.
    Thillays, F.
    Carrie, C.
    Cellier, P.
    Pommier, P.
    Laude, C.
    Mervoyer, A.
    Supiot, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E83 - E83
  • [49] Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom
    De Cock, E
    Hutton, J
    Canney, P
    Body, JJ
    Barrett-Lee, P
    Neary, MP
    Lewis, G
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1295 - 1310
  • [50] A time-in-motion study of oral ibandronate versus iv zoledronic acid for treatment of metastatic bone disease in breast cancer patients
    Wardley, A
    Body, JJ
    Neary, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 558S - 558S
12345